Image-guided surgery in head and neck cancer: Current practice and future directions of optical imaging

Head and Neck

Volumn 34, Issue 1, 2012, Pages 120-126

  Keereweer, S ^a   Sterenborg, H J C M ^a   Kerrebijn, J D F ^a   Van Driel, P B A A ^b   De Jong, R J Baatenburg ^a   Lowik C W G M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

head and neck cancer; image guided surgery; molecular imaging; near infrared fluorescence; optical imaging

Indexed keywords

BEVACIZUMAB; CD147 ANTIGEN; CETUXIMAB; CONTRAST MEDIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFERRIN RECEPTOR;

ABSORPTION; CANCER DIAGNOSIS; CANCER SURGERY; FLUORESCENCE; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MOLECULARLY TARGETED THERAPY; NEAR INFRARED FLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

CONTRAST MEDIA; FLUORESCENCE; FORECASTING; HEAD AND NECK NEOPLASMS; HUMANS; SURGERY, COMPUTER-ASSISTED;

EID: 83555172401     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21625     Document Type: Review

References (46)

1. Gulec SA, Hoenie E, Hostetter R, Schwartzentruber D,. PET probe-guided surgery: applications and clinical protocol. World J Surg Oncol 2007; 5: 65-72.
2. Hall WA, Truwit CL,. Intraoperative MR-guided neurosurgery. J Magn Reson Imaging 2008; 27: 368-375. (Pubitemid 351214043)
3. Frangioni JV,. New technologies for human cancer imaging. J Clin Oncol 2008; 26: 4012-4021.
4. DaCosta RS, Andersson H, Wilson BC,. Molecular fluorescence excitation-emission matrices relevant to tissue spectroscopy. Photochem Photobiol 2003; 78: 384-392.
5. Dhingra JK, Perrault DF Jr, McMillan K, et al. Early diagnosis of upper aerodigestive tract cancer by autofluorescence. Arch Otolaryngol Head Neck Surg 1996; 122: 1181-1186. (Pubitemid 26374844)
6. Svistun E, Alizadeh-Naderi R, El-Naggar A, Jacob R, Gillenwater A, Richards-Kortum R,. Vision enhancement system for detection of oral cavity neoplasia based on autofluorescence. Head Neck 2004; 26: 205-215. (Pubitemid 38292730)
7. Poh CF, Ng SP, Williams PM, et al. Direct fluorescence visualization of clinically occult high-risk oral premalignant disease using a simple handheld device. Head Neck 2007; 29: 71-76. (Pubitemid 46032570)
8. Roblyer D, Kurachi C, Stepanek V, et al. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res 2009; 2: 423-431.
9. Muller MG, Valdez TA, Georgakoudi I, et al. Spectroscopic detection and evaluation of morphologic and biochemical changes in early human oral carcinoma. Cancer 2003; 97: 1681-1692. (Pubitemid 36350711)
10. Delank W, Khanavkar B, Nakhosteen JA, Stoll W,. A pilot study of autofluorescent endoscopy for the in vivo detection of laryngeal cancer. Laryngoscope 2000; 110: 368-373. (Pubitemid 30143677)
11. Malzahn K, Dreyer T, Glanz H, Arens C,. Autofluorescence endoscopy in the diagnosis of early laryngeal cancer and its precursor lesions. Laryngoscope 2002; 112: 488-493. (Pubitemid 34225865)
12. Baletic N, Malicevic H, Petrovic Z, Marinkovic-Eric J, Peric A,. Advantages and limitations of the autofluorescent diagnostics of the laryngeal cancer and precancerosis. Eur Arch Otorhinolaryngol 2010; 267: 925-931.
13. Kraft M, Glanz H, von Gerlach S, Wisweh H, Lubatschowski H, Arens C,. Clinical value of optical coherence tomography in laryngology. Head Neck 2008; 30: 1628-1635.
14. De Veld DC, Witjes MJ, Sterenborg HJ, Roodenburg JL,. The status of in vivo autofluorescence spectroscopy and imaging for oral oncology. Oral Oncol 2005; 41: 117-131. (Pubitemid 40202877)
15. Amelink A, Kruijt B, Robinson DJ, Sterenborg HJ,. Quantitative fluorescence spectroscopy in turbid media using fluorescence differential path length spectroscopy. J Biomed Opt 2008; 13: 054051.
16. Pomerantz RG, Grandis JR,. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin Oncol 2004; 31: 734-743. (Pubitemid 39602679)
17. Rosenthal EL, Kulbersh BD, Duncan RD, et al. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope 2006; 116: 1636-1641. (Pubitemid 44368086)
18. Gleysteen JP, Newman JR, Chhieng D, Frost A, Zinn KR, Rosenthal EL,. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck 2008; 30: 782-789. (Pubitemid 351913856)
19. Gleysteen JP, Duncan RD, Magnuson JS, Skipper JB, Zinn K, Rosenthal EL,. Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment. Cancer Biol Ther 2007; 6: 1181-1185. (Pubitemid 351590369)
20. Kulbersh BD, Duncan RD, Magnuson JS, Skipper JB, Zinn K, Rosenthal EL,. Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch Otolaryngol Head Neck Surg 2007; 133: 511-515. (Pubitemid 46799790)
21. Withrow KP, Gleysteen JP, Safavy A, et al. Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines. Otolaryngol Head Neck Surg 2007; 137: 729-734. (Pubitemid 47632926)
22. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009; 10: 247-257.
23. Withrow KP, Newman JR, Skipper JB, et al. Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts. Technol Cancer Res Treat 2008; 7: 61-66. (Pubitemid 351238697)
24. Newman JR, Gleysteen JP, Baranano CF, et al. Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147. Cancer Biol Ther 2008; 7: 1063-1070.
25. Kearsley JH, Furlong KL, Cooke RA, Waters MJ,. An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancers. Br J Cancer 1990; 61: 821-827. (Pubitemid 20196984)
26. Shan L, Hao Y, Wang S, et al. Visualizing head and neck tumors in vivo using near-infrared fluorescent transferrin conjugate. Mol Imaging 2008; 7: 42-49.
27. Vigneswaran N, Koh S, Gillenwater A,. Incidental detection of an occult oral malignancy with autofluorescence imaging: a case report. Head Neck Oncol 2009; 1: 37-46.
28. Kruijt B, Kascakova S, de Bruijn HS, et al. In vivo quantification of chromophore concentration using fluorescence differential path length spectroscopy. J Biomed Opt 2009; 14: 034022.
29. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
30. Ogawa M, Kosaka N, Longmire MR, Urano Y, Choyke PL, Kobayashi H,. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm 2009; 6: 386-395.
31. Backer MV, Levashova Z, Patel V, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 2007; 13: 504-509. (Pubitemid 46559824)
32. Kovar JL, Volcheck WM, Chen J, Simpson MA,. Purification method directly influences effectiveness of an epidermal growth factor-coupled targeting agent for noninvasive tumor detection in mice. Anal Biochem 2007; 361: 47-54. (Pubitemid 46027009)
33. Adams KE, Ke S, Kwon S, et al. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 2007; 12: 024017.
34. Kroemer G, Pouyssegur J,. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13: 472-482. (Pubitemid 351766797)
35. Zhou H, Luby-Phelps K, Mickey BE, Habib AA, Mason RP, Zhao D,. Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial glioma of athymic mice. PLoS One 2009; 4: e8051.
36. Chen K, Xie J, Chen X,. RGD-human serum albumin conjugates as efficient tumor targeting probes. Mol Imaging 2009; 8: 65-73.
37. Jin ZH, Razkin J, Josserand V, et al. In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c(-RGDfK-) (4). Mol Imaging 2007; 6: 43-55. (Pubitemid 46642490)
38. Kossodo S, Pickarski M, Lin SA, et al. Dual in vivo quantification of integrin-targeted and protease-activated agents in cancer using fluorescence molecular tomography (FMT). Mol Imaging Biol 2010; 12: 488-499.
39. Mahmood U, Weissleder R,. Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther 2003; 2: 489-496.
40. Wunderbaldinger P, Turetschek K, Bremer C,. Near-infrared fluorescence imaging of lymph nodes using a new enzyme sensing activatable macromolecular optical probe. Eur Radiol 2003; 13: 2206-2211. (Pubitemid 37080758)
41. Mulder WJ, Castermans K, van Beijnum JR, et al. Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis 2009; 12: 17-24.
42. Kirchner C, Liedl T, Kudera S, et al. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. Nano Lett 2005; 5: 331-338. (Pubitemid 40308295)
43. Lewinski N, Colvin V, Drezek R,. Cytotoxicity of nanoparticles. Small 2008; 4: 26-49.
44. Choi J, Burns AA, Williams RM, et al. Core-shell silica nanoparticles as fluorescent labels for nanomedicine. J Biomed Opt 2007; 12: 064007.
45. Xie G, Sun J, Zhong G, Shi L, Zhang D,. Biodistribution and toxicity of intravenously administered silica nanoparticles in mice. Arch Toxicol 2009; 84: 183-190.
46. Themelis G, Yoo JS, Soh KS, Schulz R, Ntziachristos V,. Real-time intraoperative fluorescence imaging system using light-absorption correction. J Biomed Opt 2009; 14: 064012.